Houston, Texas 77030


The investigators propose a standardized prenatal management, based on the scientific evidence published in the literature, to manage prenatally fetuses with lower urinary tract obstruction (LUTO). The present study is a prospective registry that will evaluate and validate this standardized prenatal management for LUTO.

Study summary:

Patients with LUTO will come for clinical evaluation as part of the standard clinical care at the our Fetal Center. The standardized prenatal management of plan for fetuses with LUTO is described in details bellow. All pregnant women carrying fetuses with LUTO are assigned to the nurse coordinator and the prenatal records are obtained. The multidisciplinary team (maternal-fetal intervention team, pediatric urologists, pediatric nephrologist, neonatologist, genetic counselors and fetal cardiologists) will be notified. A one-day visit is planned with the following: 1. a fetal comprehensive ultrasound is scheduled for the confirmation of the diagnosis, investigation of associated anomalies and evaluation of prognostic factors; 2. a genetic counseling is performed and fetal invasive tests (FISH/fetal karyotype/fetal CMA) are offered to the patients; 3. Fetal echocardiogram is also performed to evaluate the presence of associated cardiac anomalies and the fetal cardiac function; 4. A consultation with the Fetal Intervention team (maternal-fetal specialty) is scheduled as well. If the gestational age is less than 18 weeks and isolated LUTO is confirmed on ultrasonography, patient is giving the option for prenatal expectant management, or fetal intervention or termination of pregnancy. If patient elects to proceed with fetal intervention, vesico-amniotic shunting is performed and patient is followed by ultrasound once a week. In case the shunt migrates or seems to be obstructed, we will offer repeating the procedure to the patient. If patient elects to proceed with expectant management, follow-up will be every 4 weeks. Delivery date and type of delivery depend on the obstetrical indications. For fetuses at gestational age greater than 18 and less than 30 weeks, if oligohydramnios is present, investigation of fetal renal biochemistry is offered. In case of favorable fetal renal biochemistry, vesico-amniotic shunt is offered as a fetal therapeutic intervention. In case the fetal urinary biochemistry is considered not favorable, then we will repeat the urinary examination in 24 hours. If the fetal urinary biochemistry is still not favorable, we will repeat the examination for the last time (maximum of 3 times). If it is still not favorable, then fetal vesico-amniotic shunt is not offered. However, if a fetal urinary examination reveals improvement favorable urinary biochemistry), fetal vesico-amniotic shunting is considered. Prenatal follow-up and delivery follow the same algorithm described previously. If gestational age is greater than 30 weeks and less than 34 weeks and isolated LUTO is diagnosed, fetal intervention is offered if oligohydramnios is present. If no oligohydramnios is identified, no fetal intervention is offered and patient is followed until delivery. Delivery date and type of delivery depend on the obstetrical indications. For those fetuses with gestational age greater than 34 weeks, if oligohydramnios is present, pre-term delivery is indicated. If a normal amount of amniotic fluid is seen, patient is followed weekly by ultrasound examination and delivery is at term. Fetuses with other associated anomalies independent from the gestational age will undergo further investigation with fetal magnetic resonance imaging and evaluation by the multidisciplinary team. All infants with LUTO will have the same routine standard clinical care. All infants with LUTO are evaluated postnatally by the pediatric urology and nephrology services and may need surgical intervention. At birth, the clinical evaluation will include a renal ultrasound, voiding cysto-urethrogram (VCUG) as well as clinical laboratory examinations such as serum creatinine, sodium, calcium, potassium and chloride, and a urine analysis will be performed as part of the standard clinical care. The infant will be followed every 6 months up until 24 months of life, and then annually afterwards. Information from these routine examinations will be collected and documented.


Inclusion Criteria: - Pregnant women whose fetuses have diagnosis of LUTO independently from the gestational age at diagnosis. Exclusion Criteria: - Presence of abnormal chromosomal/genetic disease - Presence of other associated structural anomaly that is not part of LUTO.



Primary Contact:

Principal Investigator
Michael Belfort, MD PHD
Baylor College of Medicine

Michael A Belfort, MD PHD
Phone: 832-826-7375
Email: belfort@bcm.edu

Backup Contact:

Email: sharhan@bcm.edu
Dina Sharhan, BS
Phone: 832-826-7451

Location Contact:

Houston, Texas 77030
United States

Michael Belfort, MD PhD
Phone: 832-826-7375
Email: belfort@bcm.edu

Site Status: Recruiting

Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.